UC DAVIS HEALTH | UC Davis Cancer Care Network

Marshall Cancer Center
Active Clinical Trials

MARSHALL

Protocol # | Title	*Local Investigator*	*Primary In/Ex Criteria*	*Primary Purpose*	*Status*	*Accrual to Date*
Breast					
A012103 | OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy	Neki	T1cN1-2 or T2-4N0-2 TNBC who achive pCR after neoadjuvant chemo	Treatment	Open to Accrual	1
NRG-CC015 | Harnessing E-Mindfulness Approaches for Living After Breast Cancer --- HEAL-ABC	Aldred	Advanced/Metastatic HR+ HER2 -disease, first line treatment	Prevention	Open to Accrual	0
BR009 | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Neki	Premenopausal; resected ER-positive/HER2-negative intermediate risk, early-stage breast cancer	Treatment	Open to Accrual	0
GI					
A212101 | Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer		New diagnosis of primary colorectal adenocarcinoma, Stage I to IV, has at least two first-degree relatives >/= 18 years old without germline testing or willing to disclose diagnosis	Screening	Open to Accrual	0
GI008 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)	Neki	Stage IIIA or IIIB, resection within 60 days	Treatment	Open to Accrual	0
Heme					
S1925 | Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study	Neki	Newly Diagnosed, Early Stage, Asymptomatic, High-Risk CLL/SLL	Treatment	Open to Accrual	1
Kidney					
S2419 | PHASE III DOUBLE BLINDED TRIAL OF IMMUNE-BASED THERAPY WITH A LIVE BIOTHERAPEUTIC MO-03 OR PLACEBO FOR FRONTLINE THERAPY OF ADVANCED CLEAR CELL RENAL CELL CARCINOMA [BIOFRONT TRIAL]	Busayavalasa	First line tx of measurable, advanced or metastatic Renal Cell Ca with Clear Cell Component	Treatment	Open to Accrual	0
Lung					
LungMAP | Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)	Busayavalasa	Stage IV or recurrent/ progressive NSCLC	Screening	Open to Accrual	0
S1800E | A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)	Neki	Non-match sub-study for LungMap with prior anti-PD-1/PD-L1 and platinum based tx for advanced NSCLC	Treatment	Open to Accrual	0

Protocol # | Title	*Local Investigator*	*Primary In/Ex Criteria*	*Primary Purpose*	*Status*	*Actual/Planned Accrual*	*Notes*
Breast						
A012303 | ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade	TBD	T1c-T3 and N0-N1 (except cT3N1 tumors, which are NOT eligible); HER 2+, pCR after NA treatment	Treatment	Pending SIV	263/1524	
EA1242: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS≤25 (RxFINE-Low)	TBD	Adjuv tx for high anatomic stage (no T4), ER+ and HER2 neg, and postmeno pts with a RS of 0-25	Treatment	Pending SIV	4/1978	
Lung						
UCDCC323 | A RANDOMIZED TRIAL OF RISK-ADAPTED, PROTEOMIC-GUIDED SYSTEMIC THERAPY FOR PREVIOUSLY UNTREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)	TBD	Stage IV or IIIC NSCLC, First line treatment	Treatment	Pending SIV	14/56	
S1900G | A Randomized Phase II Study of Capmatinib Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	TBD	EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer	Treatment	DTC approved, will be activated upon identification of a potential patient	28/44	
S1900K | A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)	TBD	MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer	Treatment	DTC approved, will be activated upon identification of a potential patient	30/56	
S1900N | A Randomized Phase II Study of Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab in Participants with Previously-Treated Actionable Genomic Alteration Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	TBD	AGA-Positive ALK, EGFR, HER2 (ERBB2), MET, NTRK, RET, and ROS1 actionable mutation previously treated with a targeted therapy and platinum-based chemotherapy	Treatment	Pending SIV	1/117	

Protocol # | Title	*Local Investigator*	*Primary In/Ex Criteria*	*Primary Purpose*	*Status*	*Actual/Planned Accrual*	*Notes*
Multiple						
UCDCC304 | Single Arm Study to Assess the Immune Effects of Fermented Wheat Germ (FWG) Nutritional Supplementation in Patients with Select Solid Malignancies Being Treated with Standard of Care Checkpoint Inhibitor-Based Therapy	TBD	Must have NSCLC, RCC, melanoma, CRC, TNBC or other solid tumor malignancy appropriate to receive SOC Cpi-based therapy	Treatment	Pending Interim Analysis	25/100	